Scientific article
French

Bon usage des antidépresseurs ISRS durant la grossesse – le défi de l'évaluation de la balance bénéfice-risque

Published in

Revue médicale suisse, vol. 12, no. 510, p. 561-566

Publication date

2016

Abstract

Studies report that between 6 and 13% of women experience symptoms of depression during pregnancy and the postpartum period. The abundant data available make selective serotonin reuptake inhibitors (SSRIs) the first line treatment in pregnancy when a pharmacological treatment is required. Risks associated with the use of SSRIs during pregnancy are limited (moderate effect size) and are often not distinguishable from those inherent to the mother's disease. Yet, several questions regarding the SSRI safety profile for the unborn child are still under debate or require additional epidemiological data. The decision of SSRI use during pregnancy needs an individual evaluation of the risk-benefit balance.

Keywords

  • Antidepressive Agents/adverse effects/therapeutic use
  • Depressive Disorder/complications/drug therapy
  • Female
  • Humans
  • Practice Patterns, Physicians'
  • Pregnancy
  • Pregnancy Complications/chemically induced/drug therapy/psychology
  • Risk Assessment
  • Serotonin Uptake Inhibitors/adverse effects/therapeutic use

Citation (ISO format)

WEISSKOPF, Etienne et al. Bon usage des antidépresseurs ISRS durant la grossesse – le défi de l’évaluation de la balance bénéfice-risque. In: Revue médicale suisse, 2016, vol. 12, n° 510, p. 561–566.

Main files (1)

Article (Published version)

Identifiers

Journal ISSN

1660-9379
705views
5downloads

Technical informations

Creation

27/07/2017 10:19:00

First validation

27/07/2017 10:19:00

Update

15/03/2023 02:15:01

Status update

15/03/2023 02:15:00

Last indexation

31/10/2024 08:22:09
All rights reserved by Archive ouverte UNIGE and the University of Geneva
OpenAIRE Indexed & Validated